Merck & Co., Inc.
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Isentress / Isentress HD (raltegravir by Year
Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — U.S. reported growth YoY (%) (%)
Merck Isentress / Isentress HD (raltegravir: -3.0% in FY2025, up 11.0 pts from a year earlier.
Where the FY2025 figure comes from
“|| Isentress/Isentress HD | 325 | 394 | -18 | 181 | 185 | -3 | 144 | 209 | -31”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 3a / 3b Product Sales.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — U.S. reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -3.0% | +11.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | -14.0% | – | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
Cite this data
StockData. (2026). Merck Isentress / Isentress HD (raltegravir (%), annual FY2024–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-isentress-us-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.